Related Attributes
Product details
Voriconazole is a broad-spectrum triazole antifungal drug, which can inhibit the activity of lanosterol 14α-demethylase and 24-methylenedihydrolanosterol demethylase in fungal cells, thus inhibiting the synthesis of ergosterol, an important substance on the cell membrane of fungal cells, resulting in the defect of fungal cell membrane, the leakage of important cell components and death.
Voriconazole has bactericidal effect on Candida spp. and Aspergillus spp. fungi, as well as on other pathogenic fungi.
Uses and functions of Voriconazole.
Voriconazole is a drug for the treatment of fungal infections, a broad-spectrum antifungal agent that is effective in the treatment of fungal infections in both humans and animals, and is on the World Health Organisation's list of essential medicines, the most effective and safest medicines required by the health system. Originally developed by Pfizer.
Voriconazole is a broad-spectrum triazole antifungal agent with the following indications: treatment of invasive aspergillosis; treatment of severe invasive infections caused by fluconazole-resistant Candida (including Candida krusei); treatment of severe infections caused by Actinobacterium spp. and Fusarium spp. of the foot; it should be used primarily for the treatment of progressive, potentially life-threatening infections in immunodeficient patients.
Drug interactions of Voriconazole.
Co-administration with CYP3A4 substrates, terfenadine, sirolimus, astemizole, cisapride, pimozide or quinidine increases the blood concentrations of the above drugs, resulting in prolongation of the Q-T interval and occasional tip-twisting ventricular tachycardia.
Combination with rifampicin, rifabutin, efavirenz, ritonavir (400 mg every 12 hours), carbamazepine and phenobarbital significantly reduces voriconazole blood concentrations.
Increased blood concentrations of ergot alkaloids (ergotamine, dihydroergotamine) in combination with ergot alkaloids can lead to ergotism.
In vitro studies of Bulk Voriconazole Powder.
Voriconazole is effective against certain conditioned filamentous and dimorphic fungi (moulds) as well as yeasts. For most of the moulds tested, with the exception of R. arrhizus and S. schenckii, Voriconazole was more active in vitro than or similar to itraconazole and amphotericin B. Voriconazole inhibited 95% of strains at ≤1 μg/ml and was able to resist up to 448 of the more recent clinical moulds.
Why choose us?
HRK Factory
About Shipping
Pharmaceutical Intermediate manufacturers
©2022 Xi'an Henrikang Biotech Co., Ltd.,